Cover Image
Market Research Report

Overactive Bladder Treatment Market - Growth, Trends, and Forecast (2019 - 2024)

Published by Mordor Intelligence LLP Product code 661179
Published Content info 111 Pages
Delivery time: 2-3 business days
Back to Top
Overactive Bladder Treatment Market - Growth, Trends, and Forecast (2019 - 2024)
Published: March 1, 2019 Content info: 111 Pages

Market Overview

  • The overactive bladder (OAB) treatment market is expected to register a CAGR of 2.9% during the forecast period. The increasing incidence of diseases, such as Parkinson's disease, which lead to the overactive bladder disorder and rising geriatric population are primary drivers of the global market.
  • In 2017, there were approximately 950 million people who were 60 years old or above, comprising 13% of the global population, and is growing by about 3% every year. Urinary incontinence generally increases with aging. OAB has a major negative impact on quality of life and health of the aged population.
  • With the increasing burden of OAB, along with other urinary diseases, the growth of the overactive bladder treatment market is likely to be high. Other factors, such as the development of innovative intravesical therapies and aggressive marketing by pharmaceuticals companies, are also expected to expand the market.

Scope of the Report

The overactive bladder treatments include various therapies, like, anticholinergics, mirabegron, etc., that are used to treat the sudden involuntary contraction of the muscle in the urinary bladder wall, leading to urinary urgency, frequency, nocturia, and urge incontinence.

Key Market Trends

Idiopathic Overactive Bladder Treatment is Expected to Have the Largest Share

Segmented by disease type, the idiopathic overactive bladder treatment accounted for a major share of the market, in 2017, which can be attributed to its high prevalence. Due to the bladder muscle weakness post pregnancy and menopause, women are more vulnerable to the condition. This is expected to encourage key companies to invest in this segment. Increasing competition among the market players may lead to a decrease in the overall cost of treatment, during the forecast period.

North America is Expected to Dominate the Overactive Bladder Treatment Market

North America is expected to lead the overactive bladder treatment market. This can be credited to its well-established healthcare industry. With reimbursement of overactive bladder treatment, the growing prevalence of the disease with rising age, and the presence of major players, the market is expected to grow during the forecast period. Due to the increasing prevalence of bladder over-activity, geriatric population, healthcare expenditure, and awareness about overactive bladder treatments, the Asia-Pacific region is expected to register the highest CAGR during the forecast period.

Competitive Landscape

The overactive bladder treatment market is moderately fragmented with global pharmaceutical companies controlling significant market share, moreover, the generic space of the market is observing a trend of consolidation and high competition. Major market players include Allergan PLC, Astellas Pharma Inc., Cogentix Medical Inc., Endo International PLC, Hisamitsu Pharmaceutical Co. Inc., Johnson & Johnson, Medtronic PLC, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Limited, and Macleods Pharmaceuticals Ltd, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support
Table of Contents
Product Code: 61502

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Aging Population and Increasing Prevalence of Diseases Causing Overactive Bladder
    • 4.2.2 Increasing Trend of Drug Development for Overactive Bladder Treatment
  • 4.3 Market Restraints
    • 4.3.1 Side Effects of Current Treatments
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Therapy
    • 5.1.1 Anticholinergics
    • 5.1.2 Mirabegron
    • 5.1.3 Neurostimulation
    • 5.1.4 Intravesical Instillation
    • 5.1.5 Other Therapies
  • 5.2 By Disease Type
    • 5.2.1 Idiopathic Overactive Bladder
    • 5.2.2 Neurogenic Overactive Bladder
  • 5.3 Geography
    • 5.3.1 North America
      • US
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • UK
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • GCC
      • South Africa
      • Rest of Middle East & Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Allergan PLC
    • 6.1.2 Astellas Pharma Inc.
    • 6.1.3 Cogentix Medical Inc.
    • 6.1.4 Endo International PLC
    • 6.1.5 Hisamitsu Pharmaceutical Co. Inc.
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Medtronic PLC
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Sanofi
    • 6.1.10 Teva Pharmaceutical Industries Limited
    • 6.1.11 Macleods Pharmaceuticals Ltd


Back to Top